Dickinson Andrew D

Dickinson Andrew D, Chief Financial Officer of Gilead Sciences (GILD), has demonstrated a clear selling bias in his recent insider transactions, with no open-market purchases recorded in the past two years. Since September 2025, Dickinson has executed 10 sales totaling approximately $3.55 million, including a $432,690 disposition on March 16, 2026, and a $463,290 sale on February 17, 2026. These transactions follow a pattern of monthly or bimonthly sales, typically ranging between $275,000 and $370,000 per transaction, with occasional larger dispositions such as the $3.55 million transaction on February 3, 2026, classified as a derivative transaction (Code F). Over his 54 reported transactions, all involving GILD, Dickinson has sold $45.7 million worth of shares while acquiring only $20 million, resulting in a net divestment position. The recent activity suggests an acceleration in selling frequency compared to historical patterns, with seven sales occurring in the six months between September 2025 and March 2026. Notably, multiple filings with zero-dollar values (Code A and M) indicate awards or option exercises without immediate market impact. The consistency of sales across multiple quarters, without offsetting buys, points to a sustained reduction in his GILD holdings rather than short-term portfolio rebalancing.